Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study
Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth
ALFASIGMA AT UEG WEEK (Vienna, 12 -15 OCTOBER 2024)
Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union
Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million
Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing...